Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Share-based Compensation (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Share-based Compensation for 10 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 184.84% to $1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 million, a 67.46% increase, with the full-year FY2024 number at $1.1 million, down 6.13% from a year prior.
  • Share-based Compensation was $1.4 million for Q3 2025 at Rein Therapeutics, up from $256000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.4 million in Q3 2025 to a low of $133000.0 in Q4 2024.
  • A 5-year average of $453526.3 and a median of $391000.0 in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: crashed 61.64% in 2024, then skyrocketed 184.84% in 2025.
  • Rein Therapeutics' Share-based Compensation stood at $607000.0 in 2021, then tumbled by 30.15% to $424000.0 in 2022, then plummeted by 36.32% to $270000.0 in 2023, then crashed by 50.74% to $133000.0 in 2024, then soared by 987.97% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Share-based Compensation are $1.4 million (Q3 2025), $256000.0 (Q2 2025), and $264000.0 (Q1 2025).